Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.74 |
| ▸ | TP53 | P04637 | 7/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.74 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063324 | 0.84 | GAA (0.76) | MAPTTP53SMN1; SMN2CDKN1AGAA | |
| SCHEMBL15614757 | 0.81 | MAPT (1.00) | MAPTTP53SMN1; SMN2CDKN1AGAA | |
| SCHEMBL15614741 | 0.81 | SMN1; SMN2 (0.67) | MAPTTP53SMN1; SMN2CDKN1ALMNA | |
| SCHEMBL22542867 | 0.81 | GAA (0.57) | MAPTTP53SMN1; SMN2CDKN1AGAA | |
| SCHEMBL30754768 | 0.81 | GAA (0.57) | MAPTTP53SMN1; SMN2CDKN1AGAA | |
| SCHEMBL26034748 | 0.81 | GAA (0.68) | MAPTTP53SMN1; SMN2CDKN1AGAA | |
| SCHEMBL20570269 | 0.79 | TP53 (0.67) | MAPTTP53SMN1; SMN2CDKN1AGAA | |
| SCHEMBL15614698 | 0.79 | GAA (0.61) | MAPTTP53SMN1; SMN2CDKN1AGAA | |
| SCHEMBL20569991 | 0.78 | GAA (0.53) | MAPTTP53SMN1; SMN2CDKN1AGAA | |
| SCHEMBL17249530 | 0.77 | GAA (0.66) | MAPTTP53SMN1; SMN2CDKN1AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210717-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG (DE) | 2015-07-30 | — | — | US | disclosed |
| WO-2014041125-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | BADEN-WÜRTTEMBERG STIFTUNG GMBH (DE) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210717-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | CDKN1A, ING2, BCCIP | MAPT 4589/4885TP53 15/4885SMN1; SMN2 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.